These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3538728)

  • 1. [Distribution of type-specific antibodies to streptococcal lipoproteinase based on population screening data].
    Benevolenskaia LI; Iontova IM; Burlev AA; Totolian AA
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Sep; (9):61-6. PubMed ID: 3538728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibodies against streptococcal lipoproteinase in the blood of healthy persons].
    Krasil'nikov IA
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Aug; (8):91-4. PubMed ID: 6758437
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antibodies to the lipoproteinase of group A hemolytic streptococci in the blood of healthy and ill persons].
    Iontova IM; Totolian AA
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Aug; (8):49-53. PubMed ID: 128270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of group A streptococcal M protein antibodies.
    Quinn RW; Vander Zwaag R; Lowry PN
    Pediatr Infect Dis; 1985; 4(4):374-8. PubMed ID: 3895177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of type-specific anti-streptococcal M-protein antibodies with biotinylated peptides in human sera.
    Kühnemund O; Schumacher F; Casaretto M; Holm SE; Lütticken R
    APMIS; 1998 Feb; 106(2):288-92. PubMed ID: 9531961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between elevated serum antibody levels to streptococcal M12 protein and susceptibility to dermatomyositis.
    Ichimiya M; Yasui H; Hirota Y; Ohmura A; Muto M
    Arch Dermatol Res; 1998 Apr; 290(4):229-30. PubMed ID: 9617445
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to streptococcal opacity factor in a selected Indian population.
    Prakash K; Dutta S
    J Med Microbiol; 1991 Feb; 34(2):119-24. PubMed ID: 1990141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibodies to the desoxyribonuclease B of Streptococcus group A in rheumatism].
    Annenkova IP; Krylov MIu; Verkhozina TK
    Vopr Revm; 1978; (4):23-7. PubMed ID: 364833
    [No Abstract]   [Full Text] [Related]  

  • 10. [A study on streptococcal prevalence in Chiang Mai, Thailand, with special reference to unusual combination between T and M antigens of group A Streptococcus].
    Murai T; Inazumi Y; Pruksakorn S
    Kansenshogaku Zasshi; 1988 Oct; 62(10):869-77. PubMed ID: 3145307
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidemiology of group A streptococcal infections--their changing frequency and severity.
    Quinn RW
    Yale J Biol Med; 1982; 55(3-4):265-70. PubMed ID: 6758372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W; Hayman W; Russell-Jones G; Good M
    Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody levels to the class I and II epitopes of the M protein and myosin are related to group A streptococcal exposure in endemic populations.
    Brandt ER; Yarwood PJ; McMillan DJ; Vohra H; Currie B; Mammo L; Pruksakorn S; Saour J; Good MF
    Int Immunol; 2001 Oct; 13(10):1335-43. PubMed ID: 11581178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
    Dale JB
    Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
    J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic evidence for a class I group A streptococcal infection among rheumatic fever patients.
    Bessen DE; Veasy LG; Hill HR; Augustine NH; Fischetti VA
    J Infect Dis; 1995 Dec; 172(6):1608-11. PubMed ID: 7594728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity.
    Froude J; Gibofsky A; Buskirk DR; Khanna A; Zabriskie JB
    Curr Top Microbiol Immunol; 1989; 145():5-26. PubMed ID: 2680297
    [No Abstract]   [Full Text] [Related]  

  • 19. Group A streptococcal adhesion. All of the theories are correct.
    Hasty DL; Courtney HS
    Adv Exp Med Biol; 1996; 408():81-94. PubMed ID: 8895780
    [No Abstract]   [Full Text] [Related]  

  • 20. Serological assessments of streptococcal infection by comparison of antibody titres to streptococcal extracellular antigens.
    el-Khateeb MS
    J Trop Pediatr; 1988 Oct; 34(5):251-3. PubMed ID: 3058993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.